GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (BSP:B1MR34) » Definitions » Cyclically Adjusted PB Ratio

Biomarin Pharmaceutical (BSP:B1MR34) Cyclically Adjusted PB Ratio : 3.95 (As of May. 01, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Biomarin Pharmaceutical Cyclically Adjusted PB Ratio?

As of today (2024-05-01), Biomarin Pharmaceutical's current share price is R$213.90. Biomarin Pharmaceutical's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was R$54.11. Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio for today is 3.95.

The historical rank and industry rank for Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio or its related term are showing as below:

BSP:B1MR34' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.76   Med: 9.02   Max: 27.64
Current: 3.76

During the past years, Biomarin Pharmaceutical's highest Cyclically Adjusted PB Ratio was 27.64. The lowest was 3.76. And the median was 9.02.

BSP:B1MR34's Cyclically Adjusted PB Ratio is ranked worse than
72.05% of 644 companies
in the Biotechnology industry
Industry Median: 1.74 vs BSP:B1MR34: 3.76

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Biomarin Pharmaceutical's adjusted book value per share data for the three months ended in Mar. 2024 was R$66.569. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is R$54.11 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biomarin Pharmaceutical Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Cyclically Adjusted PB Ratio Chart

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.80 6.23 5.32 5.41 4.56

Biomarin Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.92 4.26 4.24 4.56 4.07

Competitive Comparison of Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio falls into.



Biomarin Pharmaceutical Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=213.90/54.11
=3.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomarin Pharmaceutical's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Biomarin Pharmaceutical's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=66.569/129.4194*129.4194
=66.569

Current CPI (Mar. 2024) = 129.4194.

Biomarin Pharmaceutical Quarterly Data

Book Value per Share CPI Adj_Book
201406 11.114 100.560 14.304
201409 11.960 100.428 15.413
201412 13.537 99.070 17.684
201503 23.768 99.621 30.877
201506 22.776 100.684 29.276
201509 27.752 100.392 35.776
201512 28.841 99.792 37.403
201603 26.101 100.470 33.622
201606 20.102 101.688 25.584
201609 25.065 101.861 31.846
201612 26.870 101.863 34.139
201703 24.986 102.862 31.437
201706 26.284 103.349 32.914
201709 25.110 104.136 31.207
201712 26.315 104.011 32.743
201803 26.051 105.290 32.021
201806 30.646 106.317 37.305
201809 33.661 106.507 40.902
201812 32.330 105.998 39.474
201903 31.499 107.251 38.010
201906 31.813 108.070 38.098
201909 35.258 108.329 42.122
201912 35.632 108.420 42.533
202003 43.790 108.902 52.040
202006 46.352 108.767 55.153
202009 60.308 109.815 71.074
202012 58.116 109.897 68.440
202103 64.196 111.754 74.343
202106 58.173 114.631 65.678
202109 61.343 115.734 68.597
202112 65.580 117.630 72.153
202203 59.093 121.301 63.048
202206 61.307 125.017 63.466
202209 64.457 125.227 66.615
202212 64.820 125.222 66.993
202303 64.677 127.348 65.729
202306 61.691 128.729 62.022
202309 64.204 129.860 63.986
202312 64.321 129.419 64.321
202403 66.569 129.419 66.569

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biomarin Pharmaceutical  (BSP:B1MR34) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Biomarin Pharmaceutical Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical (BSP:B1MR34) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (BSP:B1MR34) Headlines

No Headlines